The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity ...

The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity ...

Withdrawal from methylphenidate due to serious adverse events occurred in about 1.2 out of 100 patients treated with methylphenidate. Withdrawal from methylphenidate due to any adverse events occurred ...

Medications for attention-deficit/hyperactivity disorder (ADHD) have some side effects that are common, while others are more ...

The differing time–action profiles provided by these long-acting MPH formulations may allow clinicians to target specific periods of the day that are particularly relevant for a patient ...

The objective of this review was to bring together the evidence available from head-to-head studies of long-acting MPH formulations and to increase understanding of their basic properties, discuss ...

Stanford University researchers have discovered why some people with attention deficit hyperactivity disorder may do well on their medicine for a while but struggle down the road.

Instead, participants said, classifying methylphenidate a schedule 6 drug “ negatively impacts on treatment adherence ”. Our medicines regulator, the South African Health Products Regulatory Authority ...

10mg, 20mg ext-rel tabs 5 Adults and Children: May use ER tabs in place of IR tabs when the 8hr dose of methylphenidate ER corresponds to the titrated 8hr dose of methylphenidate IR. Max 60mg/day ...